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Introduction:Whole blood functional assays are pharmacologically relevant in the drug discovery process to
evaluate potency in a relevant biological matrix, to support establishment of PK/PD relationships and to aid in
human dose predictions. However development of B cell activation assays by BCR ligation in rat whole blood
has not beenpreviously described. The aim of the present studywas to develop novelmethods of B cell activation
in rat whole blood. Methods: B cell activation in rat whole blood was evaluated by measuring CD86 up-
regulation via ﬂow cytometry. Rat B cells in whole blood were stimulated with dextran-coupled anti-IgD or a
combination of anti-IgD and TLR9 agonist. BTK, SYK, and PI3Kδ inhibitors were added to rat whole blood prior
to activation with dextran-coupled anti-IgD or anti-IgD and TLR9 agonist combination for pharmacological vali-
dation of the assay. Results: Both methods of stimulation in rat whole blood evoked robust B cell activation in a
uni-modal fashion. Highly selective inhibitors of BTK, SYK, and PI3Kδ dose-dependently attenuated B cell activity
evoked by both dextran-coupled anti-IgD and combined anti-IgD and TLR9 agonist. Compound potencies and
rank order determined by the two assays were comparable. Discussion: Two novel methods were developed
to stimulate B cells in rat whole blood, that have the potential to be used to support drug discovery efforts in
the therapeutic targeting of B cells. Furthermore, we pharmacologically validated these whole blood assays
using highly selective inhibitors of BTK, SYK, and PI3Kδ, signaling kinases which are downstream of the B cell
receptor.© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
There is a large body of evidence supporting a pathological role of
aberrant B cells in autoimmune diseases such as rheumatoid arthritis
(RA), systemic lupus erythematous (SLE) and multiple sclerosis (MS;
Edwards et al., 2004; Hauser et al., 2008; Navarra et al., 2011). B cells
have been suggested to contribute to the pathology of autoimmune
diseases due to their many biological functions, including presentation
of antigens, co-stimulation of autoreactive T cells and production of
autoantibodies (Takemura, Klimiuk, Braun, Goronzy, & Weyand, 2001;
Wither, Roy, & Brennan, 2000; Zhao et al., 2008). Indeed, pharmacolog-
ical modulation of B cell function with therapeutic antibodies such as
rituximab, belimumab and epratuzumab has demonstrated clinicallogy, Oncology & IMR, Merck
, MA 02115, USA. Tel.: +1 617
. This is an open access article underefﬁcacy in autoimmune diseases, highlighting the pathological role of
this cell type (Dörner et al., 2006; Edwards et al., 2004; Navarra et al.,
2011).
Novel mechanisms of targeting B cells are also being pursued clini-
cally. The B cell receptor (BCR) is a transmembrane protein which
upon antigen binding evokes B cell activation, proliferation and differ-
entiation (Dal Porto et al., 2004). Spleen tyrosine kinase (SYK), Bruton's
tyrosine kinase (BTK) and phosphatidylinositol-4,5-bisphosphate 3-
kinase delta (PI3Kδ) are signaling kinases downstream of the BCR
(Puri, Di Paolo, & Gold, 2013). Inhibitors of these targets are in preclin-
ical and clinical development for a variety of diseases, including the
SYK inhibitor fostamatinib, which has shown clinical efﬁcacy in RA,
and the BTK and PI3Kδ inhibitors Ibrutinib and Idelalisib respectively,
with positive therapeutic beneﬁts in chronic lymphocytic leukemia
(CLL; Weinblatt et al., 2010; Byrd et al., 2013; Brown et al., 2014).
Whole blood functional assays are pharmacologically relevant and
important in the drug discovery process to evaluate potency in a rele-
vant biological matrix, to support establishment of PK/PD relationships
and to aid in human dose predictions. BCR-mediated B cell stimulationthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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use of anti-BCR antibodies to cross-link the receptor. However develop-
ment of BCR-mediated B cell activation assays in rat whole blood has
been problematic. The exact reason for this is unclear, however the
reported higher levels of endogenous immunoglobulins in rat serum
compared to human or mouse serum, resulting in leaching of the
exogenous anti-BCR antibodies, is likely a key contributing factor
(Finkelman et al., 1980; Plebani et al., 1983; Rousseaux & Bazin, 1979;
Van Vollenhoven et al., 1989). As rat is a commonly used preclinical
species to evaluate drug efﬁcacy and safety, we sought to overcome
these issues and develop a BCR-mediated B cell stimulation assay in
rat whole blood. We leveraged two different methods of B cell stimula-
tion, utilizing dextran-coupled anti-IgD and combined use of anti-IgD
and a TLR9 agonist. With both approaches, wewere able to show robust
activation of rat B cells in whole blood. Furthermore, we demonstrated
that highly selective inhibitors of BTK, SYK, and PI3kδ showed inhibitory
pharmacologic activity in both these assays. Our studies have identiﬁed
two novelmethods of BCR-mediated B cell activation in ratwhole blood
to support drug discovery efforts in the therapeutic targeting of this cell
type and have expanded on the biology previously reported in human
and mouse B cells of BCR downstream kinase signaling pathways and
BCR/TLR synergistic effects in the rat.
2. Materials and methods
2.1. Materials
ACK lysing buffer was purchased from Lonza, and DMEM culture
media and heat inactivated fetal calf serum (FCS) were from Life
Technologies. Anti-rat IgD (clone Mard-3) was purchased from AbD
Serotec. Dextran-coupled anti-IgD, consisting of approximately 15
anti-IgD antibodies (Mard-3) per dextran molecule, was conjugated by
Fina BioSolutions. TLR9 ligands ODN2006 (5′-tcgtcgttttgtcgttttgtcgtt-3′)
and ODN2395 (5′-tcgtcgttttcggcgc:gcgccg-3′) which are synthetic DNA
molecules containing unmethylated CpG motifs, were purchased from
InvivoGen. Fluorescently labeled anti CD86 (clone 24F), CD45R (clone
HIS24), and CD3 (clone 1F4) were purchased from Becton Dickinson,
while labeled CD45RA (clone OX33) was purchased from eBioscience.
Anti-CD32/FC block (clone D34-485), mouse IgG1κ (clone MOPC21),
BD FACS lysing solution, and BD cytoﬁx were purchased from Becton
Dickinson. Ibrutinib (BTK inhibitor) and Idelalisib (PI3Kδ inhibitor)
were purchased from Cayman Chemical. Propriety BTK and SYK inhibi-
tors were synthesized at Merck as previously described (De Man et al.,
2013; Moy et al., 2013).
2.2. Animals and maintenance
Female Lewis rats (8–10 weeks, 150–175 g, Harlan Laboratories)
were pair-housed in standard ventilated cages in a 12 h light/dark
cycle and temperature-controlled environment (72 °F), relative humid-
ity: 30%–70%. Water and pelleted-chow were provided ad libitum. All
studies were performed in accordance with the National Institute of
Health Guide to the Care and Use of Laboratory Animals and the Animal
Welfare Association for the Assessment and Laboratory Animal Care
Program. The procedures were approved by the Merck Institutional
Animal Care and Use Committee.
2.2.1. Rat blood and spleen collection
Female Lewis rats were anesthetized by isoﬂurane inhalation. Blood
was carefully collected by cardiac puncture, using an 18G needle and a
syringe pre-coated with sodium heparin. The blood was transferred
into a 15 mL tube containing 100 units of sodium heparin and used im-
mediately. For spleen collection, female Lewis rats were euthanized by
carbon dioxide inhalation, and the spleen was removed. Each spleen
was placed in a 50mL tube containing DMEMmedia, and used immedi-
ately thereafter.2.3. Rat splenic B cell assay
The spleen from female Lewis rat was physically passed through a
70 μM nylon mesh directly into the media to prepare a single cell
suspension. After centrifugation, two volumes of ACK lysing buffer
were added to the cell pellet for 1 min to lyse the red blood cells. The
splenocytes were then re-suspended in media, washed, and plated in
a 96well tissue culture plate. Each well contained 1million splenocytes
in 180 μL volume of DMEM media containing 5% FCS. For compound
studies, 180 nL compound or DMSO control was added to each well
using the ECHO 520 liquid dispenser then incubated for 1 h at 37 °C.
The splenocytes were then stimulated with 3.12 μg/mL anti-IgD
(Mard-3) for 20 h, in a 37 °C humidiﬁed incubator. After incubation,
cells were washed twice with PBS/0.2% BSA solution, and then cen-
trifuged. The cell pellet was re-suspended with 10 μg/mL FC block
and incubated for 15 min on ice. Fluorescently labeled CD45R, CD3,
and CD86 antibodies were subsequently added at 1.8 μg/mL for an
additional 45 min on ice. The cells were ﬁxed in cold BD cytoﬁx for
10 min on ice, washed, re-suspended with PBS/0.2% BSA solution,
and analyzed by ﬂow cytometry. B cells were gated on CD45R+ and
CD3− cells from the cells with lymphoid scatter proﬁle, and CD86
stainingwasmeasured asMean Fluorescence Intensity (MFI) or percent
positive cells. All ﬂow cytometry analyses were performed using FlowJo
version 10 software.
2.4. Rat whole blood B cell assay
135 μL of rat whole blood was plated in each well of a 96 well tissue
culture plate. For compound studies, 135 nL inhibitor or DMSO control
was added to each well using the ECHO 520 liquid dispenser and then
incubated for 1 h at 37 °C, prior to the activation step. BCR and TLR
agonists used were anti-IgD, dextran-coupled anti-IgD, ODN2395 and
ODN2006. Corresponding isotype controls used were IgG1κ and
amino-functionalized dextran. Agonist and relevant controls were di-
rectly added to the whole blood and incubated for 20 h in a 37 °C hu-
midiﬁed incubator. After incubation, ﬂuorescently labeled CD3, CD45R
or CD45RA, and CD86 antibodies were directly added at 1.8 μg/mL for
45 min on ice. Red blood cells were lysed and the cells were ﬁxed in
one step using 20 volumes of BD lysing solution for 15min at room tem-
perature. The cells were then washed twice and re-suspended in PBS/
0.2% BSA solution, and analyzed by ﬂow cytometry. B cells were gated
on CD3− and CD45R+ or CD45RA+ cells from the cells with lymphoid
scatter proﬁle, and CD86 staining was measured as Mean Fluorescence
Intensity (MFI) or percent positive cells. All ﬂow cytometry analyses
were performed using FlowJo version 10 software.
2.5. Statistical analysis
All statistical analyses and curve ﬁtting were performed using
GraphPad Prism 6 software. Statistical signiﬁcance was determined
using one-way and two-way Anova followed by Tukey's post-test. A
p-value b 0.05 was considered as statistically signiﬁcant. Nonlinear re-
gression analysis was used to determine concentration response curves
and compound IC50 values.
3. Results
3.1. Activation of rat splenic B cells and attenuation with SYK, BTK, and
PI3Kδ inhibitors
Preliminary studies in rat splenic B cells were performed to vali-
date the use of CD86 as a marker of B cell activation. Following 20 h
of stimulation with 3.12 μg/mL anti-IgD, the splenic B cell
population displayed a uni-modal shift of 6.7 fold increase in CD86
Mean Fluorescence Intensity (MFI) or 61% CD86+ B cells relative to
the isotype control (Fig. 1A). Anti-IgD induced CD86 expression
Fig. 1. (A) Representativeﬂowcytometry histogramof CD86 up-regulation on rat splenic B cells stimulatedwith anti-IgD (dashed line) versus IgG1κ isotype control (dotted line). (B) Anti-
IgD induced CD86 expression on rat splenic B cells in the presence of SYK, BTK, and PI3Kδ inhibitors, as measured by ﬂow cytometry. Data are mean ± SD from two replicate animals.
63J. Shin et al. / Journal of Pharmacological and Toxicological Methods 71 (2015) 61–67was attenuated in a dose dependent manner with inhibitors of SYK
(Merck proprietary SYKi), BTK (Ibrutinib and Merck proprietary
BTKi) and PI3Kδ (Idelalisib; Fig. 1B).
3.2. Activation of rat B cells with dextran-coupled anti-IgD in whole blood
We next stimulated B cells in whole blood with anti-IgD or dextran-
coupled anti-IgD, for 20 h. Both agonists produced concentration
dependent up-regulation of CD86 on B cells with a greater degree ofFig. 2. (A) Representative ﬂow cytometry histogram of CD86 up-regulation on rat B cells in wh
anti-IgD (dotted line). (B) Dose–response of CD86up-regulation on rat B cells inwhole blood sti
measured by ﬂow cytometry. Data are mean ± SD from three replicate animals. *p b 0.05, **presponse observed with dextran-coupled anti-IgD versus anti-IgD
alone (Fig. 2A). Maximal absolute percentages of CD86+ B-cells were
25% following 3.75 μg/mL anti-IgD compared with 62% following
10 μg/mL dextran-coupled anti-IgD. Amino-functionalized dextran and
IgG1κ isotype control had no effects (Fig. 2B). As submaximal concen-
tration of agonist is commonly used to study the effects of compounds
in in vitro functional assays, we used the effective concentration of
95% (EC95) of 5 μg/mL dextran-coupled anti-IgD for subsequent studies
to test kinase inhibitors.ole blood stimulated with 5 μg/mL dextran-coupled anti-IgD (dashed line) or 3.75 μg/mL
mulatedwith dextran-coupled anti-IgD (diamonds) or unconjugated anti-IgD (squares), as
b 0.01, ***p b 0.001, compared to media alone (one-way Anova).
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whole blood
We next combined anti-IgD to activate BCR with TLR9 stimulation
(ODN2006 and ODN2395) based on previously published synergies
in human and mouse B cells. The TLR ligands ODN2006 and
ODN2395 speciﬁcally target TLR9 and activate B cells in similar fash-
ion (Vollmer et al., 2004). In our initial study, rat whole blood was
stimulated with a concentration of each TLR9 agonist in the presence
and absence of 15 μg/mL anti-IgD. Anti-IgD or TLR9 stimulation alone
produced modest up-regulation of CD86 and increases in the per-
centages of CD86+ B cells in whole blood (approximately 20–40%)
above the unstimulated sample (Fig. 3A, B & C). Co-stimulation
with anti-IgD and TLR9 agonists resulted in a greater increase in
the percentage of CD86+ cells in whole blood compared to either
agonist alone (Fig. 3A, B & C). Although co-stimulation with 2.5 μM
ODN2006 and 15 μg/mL anti-IgD resulted in the greatest degree
of B cell activation, co-stimulation with 2.5 μM ODN2395 and
15 μg/mL anti-IgD produced greater synergy in B cell activation.
This combination of ODN2395 and anti-IgD resulted in a 10 fold in-
crease in CD86 MFI (48% CD86+ B cells) above ODN2395 alone and
4 fold increase in CD86 MFI (26% CD86+ B cells) above anti-IgD
alone (Fig. 3C). Therefore, ODN2395 co-stimulation was chosenFig. 3. (A) and (B) Representativeﬂow cytometryhistogramof CD86 up-regulation on rat B cells
absence of 15 μg/mL anti-IgD (solid black and dashed lines, respectively). (C) Percentages of CD
ODN2395 in the presence and absence of 15 μg/mL anti-IgD. Data are mean ± SD of two r
(D) Percentages of CD86 expression on rat B cells in whole blood following dose-dependent c
**p b 0.01, ***p b 0.001 for ODN2395 and anti-IgD combinations compared to ODN2395 aloneover ODN2006 for further optimization and use in subsequent stud-
ies. Anti-IgD and ODN2395 concentrations were then cross titrated
in rat whole blood, to determine the optimal combination that re-
sulted in the greatest synergistic response. Concentration-
dependent synergistic effects were observed with ODN2395 at each
concentration of anti-IgD; altering the concentration of anti-IgD did
not result in further activation of B cells (Fig. 3D). The combination of
3.75 μg/mL anti-IgD and 2.2 μM ODN2395 resulted in the greatest de-
gree of effect compared to comparable concentrations of ODN2395
stimulation alone. These concentrations of combined agonists were
used in subsequent studies to test kinase inhibitors.3.4. Pharmacological validation of rat B cell stimulation by bothmethods in
whole blood
Treatment with highly selective inhibitors of SYK (Merck proprie-
tary SYKi), BTK (Ibrutinib and Merck proprietary BTKi) and PI3Kδ
(Idelalisib) over a range of concentrations resulted in dose-dependent
inhibition of B cell CD86 expression by both methods of stimulation
(Figs. 4A & B). Whole blood potencies for these four compounds
had the same rank order and similar potencies with both stimulation
methods (Table 1).inwhole blood stimulatedwith 2.5 μMODN2006 and 2.5 μMODN2395 in thepresence and
86 expression on rat B cells in whole blood stimulated with 2.5 μMODN2006 and 2.5 μM
eplicate animals. *p b 0.05, ***p b 0.001, compared to media alone (one-way Anova).
ross titration of anti-IgD and ODN2395. Data are mean ± SD from four replicate animals.
(two-way Anova).
Fig. 4. Effects of SYK, BTK, and PI3Kδ inhibitors on percentages of CD86 expression on rat B cells in whole blood following stimulation with (A) dextran-coupled anti-IgD and (B) anti-IgD
and ODN2395 combination. Data are mean ± SD of four replicate animals.
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Whole blood functional assays are pharmacologically relevant in
the drug discovery process to evaluate potency in a biologically rele-
vant matrix, to support the establishment of PK/PD relationships and
to aid in human dose predictions. In the case of activation and mea-
surement of immune cell activity to support the development of
drugs for inﬂammatory and autoimmune diseases, methods of B
cell activation have been reported in both human and mouse whole
blood (Xu et al., 2012). However, methods of quantiﬁcation of B
cell activity, requiring both stimulation and detection of cellular ac-
tivation in rat whole blood remain to be established. Historically, it
has been a challenge to stimulate B cells in rat whole blood using
soluble anti-IgM or anti-IgD to evoke BCR ligation likely as a result
of the reported higher levels of endogenous immunoglobulins in
rat serum compared to human or mouse serum resulting in leaching
of the exogenous anti-BCR antibodies (Finkelman et al., 1980;Table 1
Compound potencies of SYK, BTK and PI3Kδ inhibitors on B cell activation in rat whole
blood evoked by dextran-coupled anti-IgD or anti-IgD in combinationwith ODN2395. Da-
ta are mean ± SD in nanomolar of four replicate animals.
Inhibitor Dextran-coupled anti-IgD (N = 4) Anti-IgD + ODN2395 (N = 4)
SYKi 1102 ± 152 1304 ± 84
BTKi 1024 ± 23 403 ± 13
Ibrutinib 86 ± 9 49 ± 4
Idelalisib 81 ± 10 44 ± 4Plebani et al., 1983; Rousseaux & Bazin, 1979; Van Vollenhoven
et al., 1989). As rat is a highly relevant preclinical efﬁcacy and safety
species in drug discovery, we sought to overcome these issues and
develop two different methods of B cell stimulation, using dextran-
coupled anti-IgD or combined use of anti-IgD and a TLR9 agonist, in
rat whole blood. Furthermore, we validated these assays pharmacolog-
ically with the use of highly selective inhibitors of BTK, SYK, and PI3Kδ,
downstream BCR signaling kinases. These rat BCR-mediated B cell stim-
ulation assays in whole blood represent novel methods to aid in the
drug discovery process in the development of B cell therapies for the
potential treatment of inﬂammatory and autoimmune diseases.
Cross-linking of B-cell receptors by anti-Ig conjugated to highmolec-
ular weight dextran to mimic antigen-stimulation has previously been
demonstrated to greatly enhance B cell activation in puriﬁed human
and murine B cells in vitro (Brunswick et al., 1988; Rehe et al., 1990).
Compared with soluble anti-Ig antibodies, whose use is limited by re-
quirement for high molar concentrations that mediate the rapid modu-
lation of surface Ig, dextran-conjugated anti-Ig antibodies have been
shown to evoke greater B cell activation and proliferation. We adopted
this method to rat whole blood, and in similarity to what have been re-
ported in puriﬁed human and murine B cells in vitro, observed en-
hanced B cell activation, as measured by the percentage of CD86+ B
cells, with dextran-coupled anti-IgD when compared to unconjugated
anti-IgD. To our knowledge, this is the ﬁrst report on the use of
dextran-coupled anti-IgD in a whole blood system. Unconjugated anti-
IgD produced minimal increases in the percentage of CD86+ B cells in
whole blood, despite the use of high concentrations. The reason for
this remains unclear, however, we propose that high levels of endoge-
nous serum immunoglobulins in rat whole blood can leach the
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BCR. Partial occupancy is not sufﬁcient to reach the threshold for full B
cell activation and therefore, we observed suboptimal B cell activation
in whole blood despite stimulating with high concentrations of anti-
IgD (Finkelman et al., 1980; Plebani et al., 1983; Rousseaux & Bazin,
1979; Van Vollenhoven et al., 1989). Compared with dextran-coupled
anti-IgD, dextran alone did not have effects on B cell activation, suggest-
ing that the carriermoleculewas not contributing to the stimulus. These
data are consistentwith the lack of contribution of dextran in activation
of human andmurine B cells (Brunswick et al., 1988; Rehe et al., 1990).
The enhanced stimulatory capacity of dextran-coupled anti-IgD has
been proposed to be due to enhanced cross-linking of the BCR due to
the presentation of a multivalent array of anti-Ig molecules on a large
carrier molecule (Rehe et al., 1990). In further support of this mecha-
nism, we utilized highly selective pharmacological inhibitors of the
kinases, SYK (SYKi; Moy et al., 2013), BTK (Ibrutinib and a proprietary
Merck compound, BTKi; Byrd et al., 2013; De Man et al., 2013) and
PI3Kδ (Ιdelalisib; Brown et al., 2014), that mediate downstream signal-
ing following cross-linking of the BCR. Dextran-coupled anti-IgD-
evoked B cell activation in rat whole blood was inhibited by each of
the kinase inhibitors providing evidence for BCR engagement as the
mechanism mediating response to this stimulus.
In addition to the established role of the BCR in B cell function, Toll-
like receptors (TLR), a group of proteins critical to innate immune re-
sponses, are expressed in B cells and play a biological role. In this re-
spect, several groups have recently shown that TLR9, which mediates
biological responses to single stranded unmethylated CpG motifs,
synergizes with BCR to amplify B cell activation in puriﬁed human and
murine B cells (Iwata et al., 2012; Leadbetter et al., 2002). This synergy
has been proposed to play a potential pathological role in SLE where
autoreactive B cells are activated by self-derived DNA, resulting in auto-
antibody production (Christensen et al., 2005; Leadbetter et al., 2002;
Viglianti et al., 2003; Wen et al., 2013). Upon BCR ligation, the BCR
and TLR9 translocate to the auto-phagosome-like compartment
allowing for proximal BCR bound DNA antigen presentation to TLR9. B
cells are subsequently hyper-activated with increased MAPK and NF-
κB signaling, B cell proliferation andpro-inﬂammatory cytokine produc-
tion (Chaturvedi, Dorward, & Pierce, 2008; Yi, Yoon, & Krieg, 2003;
Iwata et al., 2012). In the present studies, we leveraged this reported
synergistic biology to evoke B cell activation in rat whole blood.
Expanding on previously published data in puriﬁed human and murine
B cells, synergy was observed with BCR and TLR9 co-stimulation in rat
whole blood. Our data show that partial occupancy of the BCR is evident
with either anti-IgD or TLR9 stimulation as a proportion of B cells are not
activated following administration of these agonists alone. Co-
stimulation with combined anti-IgD and TLR9 agonism enables those
B cells with partial BCR occupancy to reach the threshold for full activa-
tion, resulting in robust B cell stimulation in whole blood as measured
by increases in CD86 expression. To our knowledge, this is the ﬁrst re-
port of synergistic effects of BCR and TLR9 co-stimulation in rat B cells
and in a whole blood system. It has previously been demonstrated
that the synergistic signaling between BCR and TLR9 stimulation in pu-
riﬁed human and murine B cells is dependent on the downstream sig-
naling kinases, SYK and BTK (Iwata et al., 2012; Kenny et al., 2013).
Using highly selective inhibitors of SYK, BTK and PI3Kδ, we conﬁrmed
that the BCR and TLR9 synergistic response in rat B cells is dependent
on SYK and BTK and further show a novel role for PI3Kδ in this signaling
interaction, which has not been previously reported.
In summary, two novel methodswere developed to stimulate B cells
in rat whole blood, namely utilizing dextran-coupled anti-IgD and com-
bined use of anti-IgD and a TLR9 agonist, that have the potential to be
used to support drug discovery efforts in the therapeutic targeting of B
cells. Furthermore, we pharmacologically validated this whole blood
assay using highly selective inhibitors of BTK, SYK, and PI3Kδ, signaling
kinases that are downstream of the BCR. These studies have thus ex-
panded on the biology previously reported in human and mouse Bcells of BCR downstream kinase signaling and BCR/TLR synergistic
effects in rat B cells, and support these kinases as potential therapeutic
targets in autoimmune diseases.Acknowledgments
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